Mark Eccleston
Overview
Explore the profile of Mark Eccleston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Latarani M, Pucci P, Eccleston M, Manzo M, Gangadharannambiar P, Fischetti I, et al.
Epigenomics
. 2025 Jan;
17(3):145-154.
PMID: 39878501
Background: Aggressive Variant Prostate Cancers (AVPCs) are incurable malignancies. Platinum-based chemotherapies are used for the palliative treatment of AVPC. The Polycomb Repressive Complex 2 (PRC2) promotes prostate cancer progression histone...
2.
Zukas K, Cayford J, Serneo F, Atteberry B, Retter A, Eccleston M, et al.
J Thromb Haemost
. 2024 Jun;
22(9):2543-2554.
PMID: 38866247
Background: Neutrophils, the most abundant white blood cells in humans, play pivotal roles in innate immunity, rapidly migrating to sites of infection and inflammation to phagocytose, neutralize, and eliminate invading...
3.
Van Den Ackerveken P, Lobbens A, Pamart D, Kotronoulas A, Rommelaere G, Eccleston M, et al.
Sci Rep
. 2023 Sep;
13(1):16335.
PMID: 37770512
During cell death, nucleosomes, the basic structural unit of chromatin, are released into the blood stream and elevated levels have been found in the plasma of patients with solid cancers....
4.
Salani F, Latarani M, Casadei-Gardini A, Gangadharannambiar P, Fornaro L, Vivaldi C, et al.
Epigenomics
. 2022 Apr;
14(9):507-517.
PMID: 35473355
Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The authors tested the predictive power of circulating...
5.
Cavalier E, Guiot J, Lechner K, Dutsch A, Eccleston M, Herzog M, et al.
Front Mol Biosci
. 2021 Apr;
8:600881.
PMID: 33816549
The severity of coronavirus disease 2019 (COVID-19) varies significantly with cases spanning from asymptomatic to lethal with a subset of individuals developing Severe Acute Respiratory Syndrome (SARS) and death from...
6.
Kang N, Eccleston M, Clermont P, Latarani M, Male D, Wang Y, et al.
Epigenomics
. 2020 Sep;
12(16):1457-1476.
PMID: 32938196
Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immunoediting which ultimately leads...
7.
Eccleston M, Morris G
Per Med
. 2018 May;
5(5):441-445.
PMID: 29783450
ValiRx plc is a therapeutics and diagnostics company developing an integrated approach to the diagnosis, treatment and prognosis of cancer through its two subsidiaries; ValiPharma and ValiBio. Over 95% of...
8.
Schafer C, Paprotka T, Heitzer E, Eccleston M, Noe J, Holdenrieder S, et al.
Adv Exp Med Biol
. 2016 Oct;
924:201-215.
PMID: 27753044
Researchers working in industrial laboratories as well as in academic laboratories discussed topics related to the use of extracellular nucleic acids in different fields. These included areas like non-invasive prenatal...
9.
Bauden M, Pamart D, Ansari D, Herzog M, Eccleston M, Micallef J, et al.
Clin Epigenetics
. 2015 Oct;
7:106.
PMID: 26451166
Background: To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore...